Literature DB >> 22278605

Controversies concerning the use of neoadjuvant systemic therapy for primary breast cancer.

Manfred Kaufmann1, Thomas Karn, Eugen Ruckhäberle.   

Abstract

The major aim of neoadjuvant systemic therapy is to improve prognosis by individualizing treatment. The proven benefits of neoadjuvant systemic therapy include reducing tumor burden, higher breast-conserving surgery, and the possibility of in vivo monitoring of response to treatment. Other goals of neoadjuvant treatment are the detection of new prognostic and predictive biomarkers and the investigation of new drugs and imaging modalities. Although many prospective trials have answered important questions regarding neoadjuvant systemic therapy, several topics remain controversial.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22278605     DOI： 10.1007/s00268-012-1424-4

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


  33 in total

1.  Conditional survival among cancer patients in the United States.

Authors:  Ray M Merrill; Bradley D Hunter
Journal:  Oncologist       Date:  2010-07-20

2.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

3.  Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.

Authors:  Aman U Buzdar; Vicente Valero; Nuhad K Ibrahim; Deborah Francis; Kristine R Broglio; Richard L Theriault; Lajos Pusztai; Marjorie C Green; Sonja E Singletary; Kelly K Hunt; Aysegul A Sahin; Francisco Esteva; William F Symmans; Michael S Ewer; Thomas A Buchholz; Gabriel N Hortobagyi
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

Review 4.  Neoadjuvant endocrine treatment in primary breast cancer - review of literature.

Authors:  J Mathew; K S Asgeirsson; L R Jackson; K L Cheung; J F R Robertson
Journal:  Breast       Date:  2009-10-17       Impact factor: 4.380

5.  Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.

Authors:  W Eiermann; S Paepke; J Appfelstaedt; A Llombart-Cussac; J Eremin; J Vinholes; L Mauriac; M Ellis; M Lassus; H A Chaudri-Ross; M Dugan; M Borgs
Journal:  Ann Oncol       Date:  2001-11       Impact factor: 32.976

6.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Authors:  Rebecca Aft; Michael Naughton; Kathryn Trinkaus; Mark Watson; Lourdes Ylagan; Mariana Chavez-MacGregor; Jing Zhai; Sacha Kuo; William Shannon; Kathryn Diemer; Virginia Herrmann; Jill Dietz; Amjad Ali; Matthew Ellis; Peter Weiss; Timothy Eberlein; Cynthia Ma; Paula M Fracasso; Imran Zoberi; Marie Taylor; William Gillanders; Timothy Pluard; Joanne Mortimer; Katherine Weilbaecher
Journal:  Lancet Oncol       Date:  2010-03-31       Impact factor: 41.316

7.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Authors:  Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Alexey Manikhas; Ana Lluch; Sergey Tjulandin; Milvia Zambetti; Federico Vazquez; Mikhail Byakhow; Mikhail Lichinitser; Miguel Angel Climent; Eva Ciruelos; Belén Ojeda; Mauro Mansutti; Alla Bozhok; Roberta Baronio; Andrea Feyereislova; Claire Barton; Pinuccia Valagussa; Jose Baselga
Journal:  Lancet       Date:  2010-01-30       Impact factor: 79.321

Review 8.  Sentinel lymph node biopsy indications and controversies in breast cancer.

Authors:  Rebecca Wiatrek; Laura Kruper
Journal:  Maturitas       Date:  2011-03-15       Impact factor: 4.342

9.  Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.

Authors:  Michael A Jacobs; Ronald Ouwerkerk; Antonio C Wolff; Edward Gabrielson; Hind Warzecha; Stacie Jeter; David A Bluemke; Richard Wahl; Vered Stearns
Journal:  Breast Cancer Res Treat       Date:  2011-04-01       Impact factor: 4.872

Review 10.  Neoadjuvant systemic treatment of breast cancer.

Authors:  Issam Makhoul; Elias Kiwan
Journal:  J Surg Oncol       Date:  2011-03-15       Impact factor: 3.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.